We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Metabolic Syndrome Increases Diabetes Risk in IGT Subjects: Effects Across Diabetes Prevention Program Interventions.
- Authors
Florez, Hermes; Temprosa, Marinella; Orchard, Trevor; Mather, Kieren; Marcovina, Santica; Barrett-Connor, Elizabeth; Horton, Edward; Saudek, Christopher; Haffner, Steven; Pi-Sunyer, Xavier; Ratner, Robert; Goldberg, Ronald
- Abstract
The metabolic syndrome (MetS) is a cluster of risk factors that may be targeted for prevention of diabetes mellitus (DM). To determine MetS prevalence at baseline and its effect on DM risk, we evaluated 3234 participants with impaired glucose tolerance (IGT) in the Diabetes Prevention Program (DPP). MetS prevalence using the 2005 Adult Treatment Panel III criteria was 68.9%. After a mean follow-up of 3.2 years, the age-, sex-, and race/ethnic-adjusted hazard ratios (HR)(95%CI) (or DM in those with MetS (vs. no MetS) at baseline were 1.7(1.3-2.3), 1.7(1.2-2.4), and 2.0(1.3-3.0) for placebo, metformin, and lifestyle groups, respectively. When the MetS components were examined, placebo participants with the dyslipidemia (low HDL or high triglyceride) and obesity (large waist) components had a higher DM risk; no predictive value for DM was observed in lifestyle participants with the dyslipidemia component or for metformin participants with the obesity component (Table). As expected, the hyperglycemia component increased DM risk in all treatment groups. The hypertension component had no predictive value. When the remaining MetS components were examined after excluding hyperglycemia, obesity increased the risk of DM in placebo (HR: 1.5, 95%CI: 1.1-2.0) and lifestyle (HR: 1.6, 95% CI: 1.1-2.7) participants but not in the metformin group. These data confirm that MetS at baseline and some of its components increase the risk of DM in IGT individuals. After hyperglycemia, the most predictive component in the development of DM was obesity in the lifestyle and placebo groups and dyslipidemia in the metformin group.
- Subjects
METABOLIC syndrome; DIABETES risk factors; HEALTH promotion; CARBOHYDRATE intolerance; PLACEBOS; HIGH density lipoproteins; OBESITY; PREVENTION
- Publication
Diabetes, 2007, Vol 56, pA336
- ISSN
0012-1797
- Publication type
Article